Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulfonylureas. Why, which, and how?

A Melander1, H E Lebovitz, O K Faber

  • 1Department of Clinical Pharmacology, University of Lund, Malmö General Hospital, Sweden.

Diabetes Care
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.

Diabetes, obesity & metabolism·2015
Same author

Treatment of Patients with Obese Type 2 Diabetes with Tantalus-DIAMOND® Gastric Electrical Stimulation: Normal Triglycerides Predict Durable Effects for at Least 3 Years.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2015
Same author

Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm.

Diabetic medicine : a journal of the British Diabetic Association·2013
Same author

Electrophysiological studies in newly onset type 2 diabetes without visible vascular retinopathy.

Documenta ophthalmologica. Advances in ophthalmology·2011
Same author

Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY).

Diabetes, obesity & metabolism·2011
Same author

Use of calcium channel blockers and beta blockers as antihypertensives in relation to mortality in type 2 diabetes patients: a population-based observational study.

Pharmacoepidemiology and drug safety·2008
Same journal

A Secular Increase in the Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes.

Diabetes care·2026
Same journal

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.

Diabetes care·2026
Same journal

State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.

Diabetes care·2026
Same journal

Genetic Determinants of Macronutrient Intake Are Associated With Specific Food Intake in Youth: A Cohort Study Across Childhood and Adolescence.

Diabetes care·2026
Same journal

A Novel Electronic Medical Record Search Method to Identify Patients With Ketosis-Prone Diabetes: Implications for Discovery of Atypical Diabetes.

Diabetes care·2026
Same journal

Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Diabetes care·2026
See all related articles

Sulfonylureas effectively manage type 2 diabetes by improving insulin secretion and action. Proper use, combined with diet, can achieve euglycemia without weight gain, though hypoglycemia is a risk, especially in the elderly.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Controversies exist regarding sulfonylurea efficacy in non-insulin-dependent diabetes mellitus (NIDDM).
  • Evidence suggests sulfonylureas improve insulin secretion and action, potentially for years.
  • Proper usage with hypocaloric diets may lead to euglycemia without hyperinsulinemia or weight gain.

Purpose of the Study:

  • To evaluate the overall evidence supporting the use of sulfonylureas in NIDDM.
  • To explore mechanisms of action, efficacy, and adverse effects of sulfonylureas.
  • To provide guidance on optimal sulfonylurea therapy and administration.

Main Methods:

  • Review of existing evidence on sulfonylurea use in NIDDM.
  • Analysis of mechanisms including insulin secretion and action.

Related Experiment Videos

  • Examination of factors contributing to sulfonylurea failure and adverse events.

    • Main Results:

    • Sulfonylureas improve beta-cell function and antihyperglycemic effects, not causing exhaustion.
    • "Failures" often stem from dietary issues or delayed drug introduction.
    • Hypoglycemia, particularly long-lasting, is the primary adverse effect, especially in elderly patients.

    Conclusions:

    • Sulfonylureas remain valuable agents for NIDDM management when used appropriately.
    • Discontinuous administration may prevent desensitization; lowest effective doses are recommended.
    • Careful patient selection and monitoring are crucial to mitigate risks like hypoglycemia.